Successful synthesis of a new insulin analogue

August 8, 2017, Osaka University
Figure 1. Chemical synthesis of insulin. (a) Previous strategy based on the coupling between native insulin A- and B-chains. (b) New strategy exploiting unique nature of selenocysteine and X-ray crystal structure of selenoinsulin. (These figures are quoted from the original article with modifications.). Credit: Osaka University

A group of researchers has developed synthetic insulin analogues selenoinsulin (Se-Ins) through the replacement of the interchain disulfide in bovine pancreatic insulin (BPIns) with a diselenide bridge.

This group demonstrated that Se-Ins had a nearly identical structure and bioactivity comparable to those of BPins, and that it had enhanced resistance to IDE degradation. This holds promise for application of Se-Ins to a long-lasting insulin preparation in diabetes therapy.

After circulating in the blood stream, insulin is degraded by an insulin degrading enzyme (IDE) in the kidney and excreted in the urine. This group thought that the production of insulin with high resistance to degradation by IDE would lead to the development of a new type of long-lasting insulin preparations that could circulate in the body for a long time.

Insulin consists of two polypeptide chains: A and B chain, connected by a disulfide (Se−Se bond), so it's difficult to take insulin only from these chains because of Se−Se bonds. Thus, this group thought that if insulin A-chains and B-chains containing selenium (Se) instead of sulfur (S), were used, the diselenide bond (Se−Se bond) would be formed quickly and then the chain-assembly reaction could be carried out efficiently, as Se is more reactive than S.

Figure 2. Degradation of selenoinsulin (red) and wild-type insulin (black) by insulin-degrading enzyme (IDE). (This figure was quoted from the original article with slight modifications.). Credit: Osaka University

In addition, Se-Se bonds are more stable than S-S bonds, so this group anticipated that Se-Se bonds would give extra structural robustness on the insulin fold, thus resulting in the enhanced resistance to IDE degradation due to its intrinsic stability. Based on this concept, this group succeeded in the synthesis of Se-containing insulin A and B chains, as well as obtaining Se-Ins at the isolation yield of up to 27% by reacting peptide chains under optimal conditions.

This demonstrated that Se-Ins had a nearly identical structure to that of BPIns, suggesting that Se-Ins has a bioactivity comparable to that of BPIns. Experiments of degradation of BPIns and Se-Ins by using IDE showed that the rate of Se-Ins was much slower than that of BPIns. From this, it is thought that Se-Ins has a long-lasting nature and could be a new class of long-acting analogues for diabetes therapy.

Figure 3. Preparation of Selenoinsulin as a Long‐Lasting Insulin Analogue. Credit: Osaka University

Explore further: Insulin release is controlled by the amount of Epac2A at the secretory vesicles

More information: Kenta Arai et al. Preparation of Selenoinsulin as a Long-Lasting Insulin Analogue, Angewandte Chemie International Edition (2017). DOI: 10.1002/anie.201701654

Related Stories

Case report describes insulin autoimmune syndrome

May 7, 2017

(HealthDay)—In a case report published online May 1 in Diabetes Care, resolution of hypoglycemia and cardiovascular dysfunction after rituximab treatment of insulin autoimmune syndrome is described.

Study reveals protein to target in type 2 diabetes

September 1, 2016

When the body's cells don't respond normally to insulin—a condition known as insulin resistance—blood glucose levels can increase, resulting in type 2 diabetes. Researchers have long known that insulin resistance is linked ...

Recommended for you

A new way to make biaxial nematic phase liquid crystals

May 18, 2018

A team of researchers from the University of Colorado in the U.S. and Université Paris-Saclay, in France has developed a new way to make biaxial nematic phase liquid crystals. In their paper published in the journal Science, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.